Lipotoxicity causes hepatic cell death and therefore plays an important role in the
pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metformin, a first-line anti …

Type 2 diabetes mellitus (T2DM) predominantly considered a metabolic disease is now
being considered an inflammatory disease as well due to the involvement of meta …

Nonalcoholic fatty liver disease is associated with chronic oxidative stress. In our study, we
explored the antioxidant effect of antidiabetic metformin on chronic [high-fat diet (HFD) …

Renal fibrosis is a common pathological process where certain primary or secondary kidney
diseases can continue to progress to the end-stage of the kidney disease; however, the …

Metformin (MET) and genistein (GEN) have a beneficial role in alleviating non-alcoholic fatty
liver disease (NAFLD), but their combined effect on this disease has not yet been studied …

Increasing evidence demonstrates that berberine (BBR) is beneficial for obesity-associated
non-alcoholic fatty liver disease (NAFLD). However, it remains to be elucidated how BBR …

Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of
type 2 diabetes (T2D). As a drug that primarily targets the liver, metformin suppresses …

Methionine (Met) is not only an essential amino acid of aquatic animals, but it also regulates
lipid metabolism. To investigate the impacts of dietary Met supplementation on lipid …

Background Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic
manifestation of metabolic syndrome. Berberine (BBR) exerts anti-hyperglycemic and anti …

Metformin is used for the treatment of type 2 diabetes mellitus and has shown therapeutic
effects in preclinical models of other pathologies, such as cancer and autoimmune diseases …